Skip to main content

Rituxan Hycela

NDC 50242-109 · Genentech, Inc.

Generic namerituximab and hyaluronidase
Dosage formINJECTION, SOLUTION
RouteSUBCUTANEOUS
Active ingredient(s)RITUXIMAB, HYALURONIDASE (HUMAN RECOMBINANT)
Strength2000; 120 U/mL; mg/mL
Pharmacologic classCD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC], Endoglycosidase [EPC], Glycoside Hydrolases [CS]
Marketing categoryBLA

Packages

50242-109-01 — 1 VIAL, SINGLE-DOSE in 1 CARTON (50242-109-01) / 13.4 mL in 1 VIAL, SINGLE-DOSE

Billed under HCPCS

J9311 — Injection, rituximab 10 mg and hyaluronidase Medicare Part B payment limit (ASP + 6%): $36.39

Related Codes

Same active ingredient

FDA lists these products with the same active ingredient.

0003-3120 — nivolumab and hyaluronidase-nvhy, 0003-6120 — nivolumab and hyaluronidase-nvhy, 0069-0238 — rituximab-pvvr, 0069-0249 — rituximab-pvvr, 18657-117 — Hyaluronidase, 50242-051 — rituximab, 50242-053 — rituximab, 50242-077 — Trastuzumab and hyaluronidase-oysk, 50242-108 — rituximab and hyaluronidase, 50242-245 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-260 — pertuzumab, trastuzumab, and hyaluronidase-zzxf, 50242-554 — ocrelizumab and hyaluronidase, 50242-933 — atezolizumab and hyaluronidase-tqjs, 51662-1555 — HYALURONIDASE, 55513-224 — rituximab-arrx, 55513-326 — rituximab-arrx, 57894-503 — daratumumab and hyaluronidase-fihj (human recombinant), 57894-510 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-514 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), 57894-515 — AMIVANTAMAB and HYALURONIDASE-lpuj (HUMAN RECOMBINANT), +5 more

From the FDA National Drug Code Directory, retrieved August 24, 2026. Product listings are submitted by labelers; FDA does not verify them.